|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: CHK and KSP/Eg5 Inhibitors
La Merie Publishing, Aug 2009, Pages: 19
The present Competitive Intelligence Report about checkpoint kinase (CHK) and kinesin spindle protein (KSP) or Eg5 inhibitors provides a competitor evaluation in the field of novel molecular entities inhibiting CHK or KS/Eg5 for treatment of cancer as of August 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Progression through the cell cycle is monitored by surveillance mechanisms known as cell cycle checkpoints. Dysfunction in cell cycle checkpoints leads to genomic instability and contributes to tumor progression. Checkpoint kinase 1 (CHK-1) plays a critical role in the activation of mitotic spindle checkpoint and DNA damage checkpoint. CHK-1) has become an oncology target of significant current interest. Inhibition of CHK-1 abrogates DNA damage-induced cell cycle checkpoints and might provide therapeutic benefit. At least seven different checkpoint kinase inhibitors are in early clinical development to evaluate its role in cancer therapy. Current evidence suggests that CHK inhibitors will be most successful when combined with chemotherapy or radiotherapy.
Mitotic kinesin inhibitors target Eg5, a member of the kinesin superfamily, which plays a key role in mitosis, as it is required for the formation of a bipolar spindle. Eg5 is also known as kinesin spindle protein (KSP). At least seven different small molecules are in early clinical development. Experience with ispinesib suggested that most value of Ek5 inhibition might be found in metastatic breast, ovarian and non-small cell lung cancer, whereas experience with other Eg5 inhibitors found more value in hematologic malignancies.
The report includes a compilation of current active projects in research and development of CHK and KSP/Eg5 inhibitors in oncology. In addition, the report lists company-specific R&D pipelines of CHK and KSP/Eg5 inhibitors. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Customers who bought this item also bought
Competitor Analysis: Plk-1 Inhibitors
Competitor Analysis: Raf Inhibitors
The executive guide to Heat Shock Proteins
Nitric Oxide - Therapeutics, Markets and Companies
Molecular Diagnostics - Technologies, Markets and Companies
Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success
R&D Trends: Breast Cancer - Innovative approaches target key signaling pathways in breast tumors
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Competitor Analysis: PARP Inhibitors
Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
|
|
|
